Ligand to split in half, spinning OmniAb platform into its own company
It’s been six years since Ligand Pharmaceuticals plumped down $178 million for OMT and its antibody discovery platform OmniAb. Now, with a slate of big-name partners, it’s time for the technology to take on a new life as its own independent company, Ligand said yesterday.
Ligand is splitting into two separate, publicly traded businesses, the company announced just after the bell on Tuesday: one featuring the OmniAb business and the other housing Ligand’s existing royalties and technologies, including its Pelican protein expression platform and Captisol solubility tech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.